PhillyTablet Inquirer Daily News
philly.com
email
font size
comments
0
options
 
Thursday, July 29, 2010

Remember Safeguard Scientifics? The Wayne investment firm, run by Warren "Pete" Musser from the 1950s into the early 2000s, exploiting with varying degrees of success the eletronics, industrial-conglomerate and Internet stock bubbles, has in the past few years built a list of 17 mostly life-sciences and software plays, where it's "deployed" more than $130 million in major ownership stakes. Check it out in Safeguard's new earnings statement here.

Safeguard's next chance to score big gains through an IPO will be Conshohocken-based NuPathe Corp., which is developing a severe-migraine-headache patch.

Like Safeguard's last two IPOs, human-bladder-regeneration developer Tengion and molecule-tester Clarient, NuPathe is what venture capitalists used to call a "pre-profit" company.

Both Tengion and Clarient shares have fallen since they went public. Will NuPathe be any different? 

Posted by Joseph N. DiStefano @ 9:14 AM  Permalink | Post a comment
Comments   


0 comments
About Joseph N. DiStefano
Joseph N. DiStefano writes this blog to feed his PhillyDeals column in the Philadelphia Inquirer. Joe has been a member of Bloomberg LP’s New York Finance Team, wrote the book “Comcasted,” taught writing at St. Joseph’s University, and studied economics and history at Penn. Reach Joe at 215-854-5194 and JoeD@phillynews.com